Clinical trials

Condition   Drug Name  
Study Aalimumab vs. methotrexate in psorias: The CHAMPION (Comparative study of HumirA vs. Methotrexate vs. Placebo In psOriasis patieNts) study
Design Randomized; Double-blind
Patients 271
Treatment Regimen Adalimumab, 80 mg s.c. --> 40 mg s.c. 1x/2 wks x 15 wks; Methotrexate, 25 [max.] mg/wk p.o. x 16 wks; Placebo
Conclusions The European Quality of Life 5-Dimensional questionnaire 5D measure of general health status was improved significantly with adalimumab compared to methotrexate and placebo in chronic plaque psoriasis patients
Reference(s) Improvement in quality of life with adalimumab treatment as measured by EQ-5D: Results from CHAMPION
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1124.
Author and Affiliation Mrowietz, U., Van der Kerkhof, P., Papp, K., Saurat, J., Mcllraith, M.